Compare Sea Limited (SE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs GeneDx Holdings Corp — how do they compare? Sea Limited trades at $95.26 (market cap $56.89B), while GeneDx Holdings Corp trades at $67.97 (market cap $2.02B). The key difference: Sea Limited is far larger — about 28.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 5,359,457). Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 102 Days and GeneDx Holdings Corp for 19 Days on average.
| SE | WGS | |
|---|---|---|
Market Cap | $56.89B | $2.02B |
Volume | 5,359,457 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $188.00 | $167.51 |
52-Week Low | $78.16 | $34.51 |
Typical Hold Time | 102 Days | 19 Days |
Enterprise Value | $51.92B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $94.66, down 1.94% with bearish technical signals despite strong fundamentals. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. Analyst consensus remains strongly bullish with a $153.67 price target, representing 62% upside potential from current levels.
The stock presents a compelling growth opportunity with improving profitability and strong cash flow generation, though technical weakness and insider selling create near-term headwinds. Key risks include execution challenges in e-commerce profitability and competitive pressures in Southeast Asian markets. The disconnect between strong fundamentals and bearish technicals suggests potential for recovery if earnings momentum continues.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
